Teva Pharma Hooks Sanofi In $1.5 Billion Inflammation Deal. But Shares Tumble

Teva stock yo-yoed and then tumbled Wednesday after the company announced it would partner with French pharma giant Sanofi (SNY) to develop an inflammatory bowel disease treatment. The drug belongs to the emerging TL1A class and could eventually rival experimental treatments from Roivant Sciences…#roivantsciences #pfe #merck #prometheusbio #teva #sanofi #tevapharmaceutical #crohn #prometheus #paulhudson
Source: Reuters: Health - Category: Consumer Health News Source Type: news